Lead Product(s) : Mesdopetam
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : IRLAB
Deal Size : Inapplicable
Deal Type : Inapplicable
IRLAB's partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan
Details : Mesdopetam (IRL790) is a dopamine D3-receptor antagonist being developed for the treatment of levodopa-induced dyskinesias (LIDs), a severe form of troublesome involuntary movements commonly occurring in Parkinson's disease.
Product Name : IRL790
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2022
Lead Product(s) : Mesdopetam
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : IRLAB
Deal Size : Inapplicable
Deal Type : Inapplicable